Merck & Co. reports negative results (Q42016) offset by excellent Keytruda’s performance

US-based pharmaceutical giant Merck & Co. generated $10.1bn in sales and an EPS of $0.89 in Q4 2016 , while net income decreased by 5% to $2.47bn. Profits met expectations, while sales volume was worse than analysts predicted. The results were mainly affected by poor performance by Zetia and Vytorin (anti-cholesterol drugs), which decreased by 13%. Despite this, investors rewarded the company and its shares rose by over 3%, thanks to the impressive performance by immunotherapy Keytruda, which totaled $483m in sales, that is a 40% increase on Q3 2016.
(Source Merck & Co.)